In a Phase II clinical trial, 115 patients with metastatic BC received cisplatin plus the EGFR inhibitor cetuximab and 58 patients received cisplatin alone (Ueno and Zhang, 2011; Baselga et al., 2013). Here, EGFR is linked to breast cancer.